JPRN-jRCT1032230451招募中2 期
Phase II Pilot Study of the Efficacy and Safety of StrataXRT forRadiation Dermatitis in Breast Cancer Patients with Postoperative Radiation Therapy
Ogita Mami0 个研究点目标入组 50 人开始时间: 2023年11月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •(1) Patients who have pathological diagnosis of breast cancer
- •(2) Patients who plan to undergo whole breast irradiation after lumpectomy or post-mastectomy radiotherapy
- •(3) Patients who are eligible for radiotherapy
- •(4) Patients with Performance Status (PS) of 0 to 2
- •(5) Female patients aged 18 years old or older
- •(6) Patients who have provided written consent
- •(7) Outpatient
排除标准
- •(1) Patients with distant metastasis
- •(2) Patients with a history of radiation therapy to the treatment area
- •(3) Patients requiring concurrent bilateral breast radiation
- •(4) Patients requiring partial breast radiation
- •(5) Patients with active rash, pre-existing dermatitis, or any skin conditions within the treatment area that prevents skin assessment for the study
- •(6) Patients who are allergic to silicone
- •(7) Patients participating in other clinical trials
- •(8) Patients whom the Principal Investigator or Co-Investigator has determined to be unsuitable for participation in this study
研究者
相似试验
未知
2 期
A Phase 2 Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With MicroalbuminuriaType 2 Diabetes MellitusJPRN-jRCT2080222722DAIICHISANKYO Co.,Ltd.325
招募中
2 期
A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab- and Talquetamab-based Combination Regimens in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma2024-517382-17-00Universitaetsklinikum Heidelberg AöR130
进行中（未招募）
1 期
Study of Tislelizumab (BGB-A317) Combined With or Without BGB-A1217 in Patients With Previously Treated Recurrent or Metastatic Cervical CancerEUCTR2020-004657-77-PLBeiGene, Ltd. c/o BeiGene USA, Inc.167
进行中（未招募）
1 期
Study of Tislelizumab (BGB-A317) Combined With or Without BGB-A1217 in Patients With Previously Treated Recurrent or Metastatic Cervical CancerEUCTR2020-004657-77-BGBeiGene, Ltd.167
已完成
1 期
A Phase I/IIa Study of the Efficacy and Safety of ASN-002 Alone and in Combination with 5-Fluorouracil (5-FU) in Adult Patients with Low-Risk Nodular Basal Cell CarcinomaACTRN12615001017516Ascend Biopharmaceutical Ltd.16